| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 89 | 2022 | 4946 | 4.010 |
Why?
|
| Anti-HIV Agents | 32 | 2021 | 1275 | 2.770 |
Why?
|
| Nevirapine | 17 | 2018 | 146 | 2.220 |
Why?
|
| HIV-1 | 29 | 2020 | 1239 | 1.940 |
Why?
|
| Infectious Disease Transmission, Vertical | 26 | 2022 | 467 | 1.760 |
Why?
|
| Lopinavir | 19 | 2021 | 137 | 1.720 |
Why?
|
| Pregnancy Complications, Infectious | 15 | 2022 | 507 | 1.670 |
Why?
|
| Anti-Retroviral Agents | 16 | 2021 | 542 | 1.630 |
Why?
|
| HIV Protease Inhibitors | 12 | 2018 | 92 | 1.320 |
Why?
|
| Female | 82 | 2022 | 8751 | 1.300 |
Why?
|
| Infant | 49 | 2018 | 2145 | 1.240 |
Why?
|
| Ritonavir | 16 | 2021 | 137 | 1.230 |
Why?
|
| Humans | 98 | 2023 | 14077 | 1.200 |
Why?
|
| Child, Preschool | 40 | 2019 | 1675 | 1.190 |
Why?
|
| Benzoxazines | 10 | 2021 | 119 | 1.170 |
Why?
|
| Male | 60 | 2022 | 6489 | 1.170 |
Why?
|
| Viral Load | 28 | 2021 | 808 | 1.150 |
Why?
|
| Child | 39 | 2023 | 2180 | 1.150 |
Why?
|
| Antiretroviral Therapy, Highly Active | 12 | 2017 | 468 | 1.130 |
Why?
|
| Drug Resistance, Viral | 10 | 2016 | 268 | 1.080 |
Why?
|
| South Africa | 58 | 2023 | 7312 | 0.950 |
Why?
|
| Bone Density | 6 | 2022 | 103 | 0.720 |
Why?
|
| Dideoxynucleosides | 3 | 2018 | 29 | 0.700 |
Why?
|
| Treatment Outcome | 19 | 2018 | 867 | 0.700 |
Why?
|
| HIV | 7 | 2018 | 380 | 0.670 |
Why?
|
| Blood | 4 | 2015 | 51 | 0.650 |
Why?
|
| Infant, Newborn | 24 | 2021 | 1410 | 0.600 |
Why?
|
| Pregnancy | 21 | 2022 | 1815 | 0.570 |
Why?
|
| Developmental Disabilities | 1 | 2016 | 22 | 0.530 |
Why?
|
| Calcaneus | 3 | 2022 | 14 | 0.510 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 2 | 2013 | 33 | 0.500 |
Why?
|
| Mutation, Missense | 4 | 2015 | 65 | 0.490 |
Why?
|
| Cohort Studies | 18 | 2021 | 939 | 0.470 |
Why?
|
| Polymerase Chain Reaction | 8 | 2020 | 260 | 0.470 |
Why?
|
| Stavudine | 5 | 2018 | 78 | 0.470 |
Why?
|
| Alkynes | 10 | 2021 | 113 | 0.450 |
Why?
|
| Cyclopropanes | 10 | 2021 | 119 | 0.450 |
Why?
|
| Nervous System | 1 | 2013 | 3 | 0.450 |
Why?
|
| HIV Reverse Transcriptase | 2 | 2014 | 38 | 0.440 |
Why?
|
| Drug Therapy, Combination | 10 | 2018 | 271 | 0.440 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2013 | 10 | 0.420 |
Why?
|
| Reagent Kits, Diagnostic | 3 | 2017 | 56 | 0.420 |
Why?
|
| Prenatal Care | 3 | 2022 | 141 | 0.410 |
Why?
|
| Sensitivity and Specificity | 9 | 2019 | 380 | 0.410 |
Why?
|
| Child Development | 1 | 2013 | 89 | 0.410 |
Why?
|
| Cross-Sectional Studies | 11 | 2021 | 1377 | 0.400 |
Why?
|
| HIV Antibodies | 2 | 2015 | 243 | 0.400 |
Why?
|
| Lipids | 4 | 2018 | 81 | 0.390 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 56 | 0.370 |
Why?
|
| Maternal Exposure | 1 | 2010 | 14 | 0.360 |
Why?
|
| Protease Inhibitors | 1 | 2010 | 23 | 0.360 |
Why?
|
| HIV Protease | 3 | 2016 | 21 | 0.350 |
Why?
|
| Saliva | 1 | 2010 | 22 | 0.340 |
Why?
|
| CD4 Lymphocyte Count | 9 | 2020 | 654 | 0.340 |
Why?
|
| Mass Screening | 2 | 2017 | 242 | 0.330 |
Why?
|
| RNA, Viral | 8 | 2017 | 303 | 0.320 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2013 | 326 | 0.320 |
Why?
|
| Bone and Bones | 2 | 2020 | 38 | 0.310 |
Why?
|
| Sustained Virologic Response | 2 | 2019 | 22 | 0.300 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2008 | 59 | 0.300 |
Why?
|
| Killer Cells, Natural | 4 | 2011 | 50 | 0.280 |
Why?
|
| Longitudinal Studies | 7 | 2020 | 409 | 0.280 |
Why?
|
| Neonatal Screening | 4 | 2017 | 24 | 0.280 |
Why?
|
| Viremia | 4 | 2016 | 66 | 0.270 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2017 | 73 | 0.270 |
Why?
|
| Body Composition | 3 | 2018 | 150 | 0.270 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2018 | 150 | 0.270 |
Why?
|
| Communication | 2 | 2016 | 56 | 0.260 |
Why?
|
| Time Factors | 7 | 2019 | 503 | 0.250 |
Why?
|
| Bone Remodeling | 3 | 2021 | 11 | 0.250 |
Why?
|
| Sequence Analysis, DNA | 4 | 2015 | 180 | 0.240 |
Why?
|
| Adult | 15 | 2021 | 5664 | 0.240 |
Why?
|
| Algorithms | 1 | 2005 | 105 | 0.240 |
Why?
|
| Cardiopulmonary Resuscitation | 3 | 2010 | 23 | 0.240 |
Why?
|
| Body Weights and Measures | 2 | 2016 | 17 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 123 | 0.240 |
Why?
|
| Case-Control Studies | 7 | 2020 | 464 | 0.230 |
Why?
|
| Medication Adherence | 3 | 2014 | 137 | 0.230 |
Why?
|
| Chemoprevention | 3 | 2014 | 33 | 0.230 |
Why?
|
| Ultrasonography | 3 | 2022 | 77 | 0.220 |
Why?
|
| DNA, Viral | 3 | 2018 | 165 | 0.220 |
Why?
|
| Mobile Applications | 1 | 2023 | 12 | 0.220 |
Why?
|
| Prevalence | 5 | 2017 | 1149 | 0.220 |
Why?
|
| Physicians | 1 | 2023 | 30 | 0.220 |
Why?
|
| Telemedicine | 1 | 2023 | 25 | 0.220 |
Why?
|
| Lamivudine | 3 | 2013 | 86 | 0.210 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 405 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2022 | 39 | 0.200 |
Why?
|
| Retrospective Studies | 7 | 2015 | 767 | 0.200 |
Why?
|
| Chemokine CCL3 | 3 | 2012 | 23 | 0.200 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2010 | 145 | 0.190 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 367 | 0.190 |
Why?
|
| Receptors, KIR | 2 | 2011 | 23 | 0.190 |
Why?
|
| Advanced Cardiac Life Support | 2 | 2010 | 2 | 0.180 |
Why?
|
| Adolescent | 10 | 2020 | 2858 | 0.180 |
Why?
|
| Gene Dosage | 2 | 2012 | 23 | 0.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2010 | 43 | 0.180 |
Why?
|
| Problem Behavior | 1 | 2020 | 6 | 0.180 |
Why?
|
| Pyrimidinones | 2 | 2010 | 24 | 0.180 |
Why?
|
| Emergency Medical Services | 2 | 2010 | 26 | 0.180 |
Why?
|
| Viral Proteins | 2 | 2010 | 30 | 0.170 |
Why?
|
| Anthropometry | 3 | 2018 | 101 | 0.170 |
Why?
|
| Mitochondria | 1 | 2019 | 12 | 0.170 |
Why?
|
| DNA, Mitochondrial | 1 | 2019 | 31 | 0.170 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 17 | 0.170 |
Why?
|
| Educational Status | 1 | 2019 | 68 | 0.160 |
Why?
|
| Antitubercular Agents | 2 | 2013 | 299 | 0.160 |
Why?
|
| Risk Factors | 4 | 2017 | 1431 | 0.160 |
Why?
|
| Quality of Life | 1 | 2020 | 170 | 0.160 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 153 | 0.160 |
Why?
|
| Cytochrome P-450 CYP2B6 | 2 | 2016 | 16 | 0.160 |
Why?
|
| Drug Substitution | 1 | 2018 | 29 | 0.150 |
Why?
|
| Genotyping Techniques | 2 | 2015 | 38 | 0.150 |
Why?
|
| Growth | 1 | 2018 | 14 | 0.150 |
Why?
|
| Haplotypes | 3 | 2016 | 119 | 0.150 |
Why?
|
| Point-of-Care Systems | 1 | 2019 | 88 | 0.150 |
Why?
|
| Aging | 1 | 2018 | 109 | 0.140 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2009 | 194 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 190 | 0.140 |
Why?
|
| Desiccation | 2 | 2015 | 15 | 0.140 |
Why?
|
| Cardiovascular Diseases | 2 | 2010 | 235 | 0.140 |
Why?
|
| Malnutrition | 1 | 2017 | 53 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2017 | 20 | 0.140 |
Why?
|
| HIV Core Protein p24 | 2 | 2007 | 18 | 0.140 |
Why?
|
| Bone Development | 1 | 2016 | 19 | 0.140 |
Why?
|
| Problem Solving | 1 | 2016 | 3 | 0.140 |
Why?
|
| Developing Countries | 3 | 2017 | 385 | 0.140 |
Why?
|
| Amino Acid Substitution | 3 | 2016 | 35 | 0.140 |
Why?
|
| Child of Impaired Parents | 1 | 2016 | 9 | 0.140 |
Why?
|
| Psychomotor Performance | 1 | 2016 | 12 | 0.140 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 68 | 0.140 |
Why?
|
| Health Care Costs | 2 | 2019 | 107 | 0.140 |
Why?
|
| Diet | 1 | 2017 | 108 | 0.140 |
Why?
|
| Mutation | 2 | 2016 | 299 | 0.130 |
Why?
|
| Specimen Handling | 2 | 2015 | 103 | 0.130 |
Why?
|
| Truth Disclosure | 1 | 2016 | 18 | 0.130 |
Why?
|
| Gene Products, gag | 1 | 2016 | 11 | 0.130 |
Why?
|
| Central Nervous System | 1 | 2016 | 11 | 0.130 |
Why?
|
| Treatment Failure | 4 | 2018 | 175 | 0.130 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2015 | 20 | 0.120 |
Why?
|
| Absorptiometry, Photon | 3 | 2022 | 83 | 0.120 |
Why?
|
| Urban Health | 1 | 2015 | 78 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 41 | 0.120 |
Why?
|
| Body Weight | 2 | 2012 | 110 | 0.120 |
Why?
|
| Postnatal Care | 1 | 2014 | 13 | 0.120 |
Why?
|
| Age Factors | 4 | 2018 | 364 | 0.120 |
Why?
|
| Cytokines | 3 | 2009 | 107 | 0.120 |
Why?
|
| Tuberculosis | 2 | 2011 | 530 | 0.120 |
Why?
|
| Preventive Health Services | 1 | 2014 | 17 | 0.110 |
Why?
|
| Language Development | 1 | 2013 | 4 | 0.110 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2013 | 19 | 0.110 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 55 | 0.110 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2014 | 184 | 0.110 |
Why?
|
| Exercise | 1 | 2016 | 203 | 0.110 |
Why?
|
| Molecular Sequence Data | 2 | 2015 | 263 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2012 | 168 | 0.110 |
Why?
|
| Fatal Outcome | 1 | 2013 | 21 | 0.110 |
Why?
|
| Cognition | 1 | 2013 | 75 | 0.110 |
Why?
|
| Heart Arrest | 3 | 2010 | 9 | 0.110 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2012 | 8 | 0.110 |
Why?
|
| Hospitals | 2 | 2018 | 102 | 0.100 |
Why?
|
| Antirheumatic Agents | 1 | 2013 | 34 | 0.100 |
Why?
|
| Somatotypes | 1 | 2012 | 3 | 0.100 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2012 | 6 | 0.100 |
Why?
|
| Epilepsy, Absence | 1 | 2011 | 2 | 0.100 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2011 | 6 | 0.100 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 8 | 0.100 |
Why?
|
| Parturition | 1 | 2011 | 30 | 0.090 |
Why?
|
| HLA-C Antigens | 1 | 2011 | 15 | 0.090 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 49 | 0.090 |
Why?
|
| HLA Antigens | 1 | 2011 | 50 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2011 | 120 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2019 | 1131 | 0.090 |
Why?
|
| Genotype | 4 | 2011 | 430 | 0.080 |
Why?
|
| Young Adult | 4 | 2019 | 2357 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 59 | 0.080 |
Why?
|
| BCG Vaccine | 1 | 2009 | 20 | 0.080 |
Why?
|
| DNA Methylation | 2 | 2019 | 19 | 0.080 |
Why?
|
| Biomarkers | 2 | 2021 | 322 | 0.080 |
Why?
|
| Growth Disorders | 2 | 2019 | 56 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2018 | 149 | 0.070 |
Why?
|
| Immunoassay | 1 | 2007 | 28 | 0.070 |
Why?
|
| Chemokines, CC | 1 | 2007 | 15 | 0.070 |
Why?
|
| Phlebotomy | 1 | 2006 | 6 | 0.070 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2010 | 320 | 0.070 |
Why?
|
| Drug Monitoring | 2 | 2016 | 55 | 0.060 |
Why?
|
| AIDS Serodiagnosis | 1 | 2005 | 44 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2004 | 10 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2004 | 89 | 0.060 |
Why?
|
| Registries | 1 | 2004 | 89 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 163 | 0.060 |
Why?
|
| Research Design | 1 | 2004 | 123 | 0.060 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2018 | 113 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2016 | 532 | 0.050 |
Why?
|
| Health Personnel | 1 | 2023 | 229 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 103 | 0.050 |
Why?
|
| Africa South of the Sahara | 2 | 2012 | 328 | 0.050 |
Why?
|
| Respiration, Artificial | 2 | 2010 | 46 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 280 | 0.040 |
Why?
|
| Echocardiography | 2 | 2010 | 99 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 58 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 230 | 0.040 |
Why?
|
| CpG Islands | 1 | 2019 | 6 | 0.040 |
Why?
|
| Education | 1 | 2019 | 22 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2019 | 39 | 0.040 |
Why?
|
| Lipodystrophy | 1 | 2018 | 7 | 0.040 |
Why?
|
| Telomere | 1 | 2018 | 17 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2018 | 22 | 0.040 |
Why?
|
| Collagen Type I | 1 | 2018 | 6 | 0.040 |
Why?
|
| Peptides | 1 | 2018 | 40 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2017 | 7 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 12 | 0.040 |
Why?
|
| Dyslipidemias | 1 | 2018 | 47 | 0.040 |
Why?
|
| Recommended Dietary Allowances | 1 | 2017 | 11 | 0.040 |
Why?
|
| Incidence | 2 | 2010 | 655 | 0.040 |
Why?
|
| Hospitals, Maternity | 1 | 2017 | 4 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 128 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 23 | 0.040 |
Why?
|
| Lost to Follow-Up | 1 | 2017 | 62 | 0.040 |
Why?
|
| Self Report | 1 | 2017 | 111 | 0.040 |
Why?
|
| Patient Identification Systems | 1 | 2017 | 4 | 0.040 |
Why?
|
| Foot | 1 | 2016 | 5 | 0.030 |
Why?
|
| Contact Tracing | 1 | 2017 | 47 | 0.030 |
Why?
|
| Child Health Services | 1 | 2016 | 33 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2016 | 14 | 0.030 |
Why?
|
| Gene Expression | 1 | 2016 | 43 | 0.030 |
Why?
|
| Counseling | 1 | 2017 | 136 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2018 | 312 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 144 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 2015 | 25 | 0.030 |
Why?
|
| Animals | 1 | 2018 | 1063 | 0.030 |
Why?
|
| Mothers | 1 | 2017 | 190 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 57 | 0.030 |
Why?
|
| Plasma | 1 | 2014 | 39 | 0.030 |
Why?
|
| Alleles | 1 | 2014 | 134 | 0.030 |
Why?
|
| Health Services Research | 1 | 2014 | 57 | 0.030 |
Why?
|
| Sex Factors | 1 | 2014 | 224 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2013 | 132 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2012 | 40 | 0.030 |
Why?
|
| CD4 Antigens | 1 | 2012 | 47 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 23 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 38 | 0.020 |
Why?
|
| Breast Feeding | 2 | 2004 | 119 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 45 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2012 | 79 | 0.020 |
Why?
|
| Body Height | 1 | 2012 | 51 | 0.020 |
Why?
|
| Receptors, KIR2DL1 | 1 | 2011 | 5 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 59 | 0.020 |
Why?
|
| Infant, Low Birth Weight | 1 | 2011 | 33 | 0.020 |
Why?
|
| HLA-B Antigens | 1 | 2011 | 12 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 235 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 40 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 41 | 0.020 |
Why?
|
| Risk Adjustment | 1 | 2011 | 3 | 0.020 |
Why?
|
| Drug Dosage Calculations | 1 | 2011 | 8 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 96 | 0.020 |
Why?
|
| Polypharmacy | 1 | 2011 | 5 | 0.020 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 29 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2011 | 41 | 0.020 |
Why?
|
| Ligands | 1 | 2011 | 33 | 0.020 |
Why?
|
| Middle Aged | 1 | 2019 | 3425 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2010 | 22 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 124 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2010 | 39 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 117 | 0.020 |
Why?
|
| Ethionamide | 1 | 2010 | 9 | 0.020 |
Why?
|
| Premature Birth | 1 | 2011 | 76 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2009 | 14 | 0.020 |
Why?
|
| Isoniazid | 1 | 2010 | 110 | 0.020 |
Why?
|
| Risk | 1 | 2009 | 87 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 65 | 0.020 |
Why?
|
| Rifampin | 1 | 2010 | 189 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2008 | 6 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2008 | 13 | 0.020 |
Why?
|
| Disease Progression | 1 | 2008 | 154 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2007 | 9 | 0.020 |
Why?
|
| Chemokine CCL4 | 1 | 2007 | 14 | 0.020 |
Why?
|
| Fetal Blood | 1 | 2007 | 27 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2006 | 14 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 183 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 210 | 0.020 |
Why?
|
| Bias | 1 | 2004 | 12 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2004 | 12 | 0.020 |
Why?
|
| Poverty | 1 | 2005 | 149 | 0.010 |
Why?
|
| International Cooperation | 1 | 2004 | 50 | 0.010 |
Why?
|
| Data Collection | 1 | 2004 | 86 | 0.010 |
Why?
|